Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 4 clinical trials
A Randomized, Open Label, Multi-center, Comparative Trial, to Assess the Efficacy and Safety of Pritelivir Versus Foscarnet for the Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (PRIOH-1) (PRIOH-1)

infection, treated with pritelivir 100 mg once daily (following a loading dose of 400 mg as first dose to rapidly reach steady-state plasma concentration) or foscarnet 40 mg/kg every 8 hours or 60 mg/kg

valacyclovir
vasectomy
renal function
neutropenia
acyclovir
  • 16821 views
  • 25 Oct, 2022
  • 51 locations
CMV-TCR-T Cells for Refractory CMV Infection After HSCT

This is a single centre, single arm, open-label, phase I study to evaluate the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating refractory CMV infection after HSCT.

  • 0 views
  • 29 Oct, 2021
  • 1 location
AntiCMV mol cules Monitoring in Real-life in Stem Cell Recipients

prophylaxis in France. Foscarnet, iv-administered and nephrotoxic, remains less used. There is thus a high expectation from less toxic molecules for prophylaxis The development letermovir recently available

  • 0 views
  • 27 Jan, 2021
  • 1 location
Breakthrough CMV Lung Transplant -Multicentre

Cytomegalovirus (CMV) infection is the most common opportunistic infection in lung transplantation leading to direct and indirect effects that can result in life threatening complications. The risk of CMV infection is highest when the recipient of the transplant has never been in contact with CMV (negative immunity) and the donor …

  • 0 views
  • 04 Oct, 2022
  • 1 location